02613nas a2200217 4500008004100000245018300041210006900224260001700293300001400310490000700324520183400331653000902165653002202174653002202196653002702218100003102245700003102276700001902307700003302326856003602359 2024 eng d00aChanges in Blood Brain-Derived Neurotrophic Factor (BDNF) Levels in Experimental Animals with Traumatic Brain Injury after Magnesium Sulfate Administration: An Experimental Study0 aChanges in Blood BrainDerived Neurotrophic Factor BDNF Levels in cOctober 2024 a1086-10890 v163 a

Background: Traumatic brain injury (TBI) results in notable impairments in neurological function and is associated with poor outcomes. Various processes occur at the cellular level, one of which is neuroinflammation. Brain-derived neurotrophic factor (BDNF) is a neurotrophin protein produced by the brain that circulates in plasma post-injury. It has functions such as anti-apoptosis, anti-neurotoxicity, and antiinflammatory effects. Therapeutic approaches aimed at modulating or synergizing BDNF are anticipated to reduce inflammation and enhance outcomes in TBI patients. Magnesium sulfate administration is known for its anti-inflammatory and neuroprotective effects. Methods: This study employed a true experimental post-test-only group design. The subjects, male Wistar rats (Rattus norvegicus), were subjected to weight-drop-induced TBI and divided into three distinct groups: a control group (Group A), a TBI group without therapy (Group B), and a therapy group (Group C). Group B received TBI without magnesium sulfate administration, while Group C received TBI with magnesium sulfate administered at 250 μm/kg BW. BDNF levels in blood plasma were assessed at the conclusion of therapy utilizing ELISA. ANOVA was used to conclude the inquiry after all groups underwent a Shapiro-Wilk test. Results: Plasma BDNF levels were significantly lower in the TBI rat models treated with magnesium sulfate at 250 μm/kg BW within 4 hours after injury than in the untreated group (p = 0.005). Compared to the untreated group, the magnesium sulfate-treated group had reduced plasma BDNF levels. Conclusions: Administration of MgSO4 to the TBI treatment group resulted in decreased BDNF levels compared to the untreated group.

10aBDNF10aMagnesium sulfate10aNeuroinflammation10aTraumatic Brain Injury1 aSujaka, Aditya, Brahmantio1 aAirlangga, Prananda, Surya1 aApriawan, Tedy1 aParenrengi, Muhammad, Arifin uhttps://phcogj.com/article/2387